Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBIT (2019 - 2025)

Historic EBIT for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$44.9 million.

  • Allogene Therapeutics' EBIT rose 3744.11% to -$44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$227.4 million, marking a year-over-year increase of 2364.43%. This contributed to the annual value of -$273.2 million for FY2024, which is 1664.08% up from last year.
  • Latest data reveals that Allogene Therapeutics reported EBIT of -$44.9 million as of Q3 2025, which was up 3744.11% from -$56.8 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' EBIT ranged from a high of $1.7 million in Q4 2021 and a low of -$99.1 million during Q1 2023
  • Moreover, its 5-year median value for EBIT was -$71.4 million (2024), whereas its average is -$67.6 million.
  • As far as peak fluctuations go, Allogene Therapeutics' EBIT soared by 10246.1% in 2021, and later crashed by 574704.16% in 2022.
  • Over the past 5 years, Allogene Therapeutics' EBIT (Quarter) stood at $1.7 million in 2021, then crashed by 5747.04% to -$96.4 million in 2022, then grew by 11.71% to -$85.1 million in 2023, then increased by 28.93% to -$60.5 million in 2024, then rose by 25.77% to -$44.9 million in 2025.
  • Its EBIT stands at -$44.9 million for Q3 2025, versus -$56.8 million for Q2 2025 and -$65.2 million for Q1 2025.